Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Free cash flow
Kiniksa Pharmaceuticals International (KNSA) free cash flow by quarter
Kiniksa Pharmaceuticals International's free cash flow was $47.4M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $22.2M (Q1 2025) to $53.3M (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $47.4M | +2% | +44% |
| Q2 2026 | $46.5M | -7% | +67% |
| Q1 2026 | $50.0M | -6% | +125% |
| Q4 2025 | $53.3M | +61% | — |
| Q3 2025 | $33.0M | +18% | — |
| Q2 2025 | $27.9M | +26% | — |
| Q1 2025 | $22.2M | — | — |
Q3 2026 at a glance
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kiniksa Pharmaceuticals International's free cash flow?
Kiniksa Pharmaceuticals International's free cash flow was $47.4M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Kiniksa Pharmaceuticals International's free cash flow changed?
Over the last 7 quarters it ranged from $22.2M (Q1 2025) to $53.3M (Q4 2025).
Q3 2026 results → · How Kiniksa Pharmaceuticals International makes money →